title: In vitro tumoral progression of human bladder carcinoma: role for TGFbeta.
abstract: OBJECTIVE
  Investigating whether extracellular factors are possible actors in tumoral progression in bladder carcinoma.
  
  
  METHODS
  RT112/G2 bladder tumour cells were grown in presence of TGFbeta and analysed by immunological and cDNA microarray techniques.
  
  
  RESULTS
  TGFbeta inhibited cell proliferation, reduced TNFalpha- and IFNgamma-induced apoptosis by decreasing TNFalpha-RI and IFNgamma-R antigen expression. It also inhibited cleaved caspase 8 and 9 expression, decreased E-cadherin, and increased BclxL and cyclooxygenase-2 expression. The cDNA microarray approach showed that TGFbeta up-regulated the expression of genes with defined roles in tumoral progression sometimes associated with poor outcome in bladder cancer.
  
  
  CONCLUSIONS
  These results suggest that a part of the bladder tumoral progression process may be related to the action of exogenous TGFbeta confirming the possible role for the microenvironment.
authors.affiliation: Laboratoires de Cytologie, Centre Hospitalier Universitaire de Grenoble, Departement d'Anatomie et Cytologie Pathologique, Hôpital A. Michallon, BP 217, 38043 Grenoble cedex 09, France. pchampelovier@chu-grenoble.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Champelovier
authors.forename: Michèle
authors.initials: M
authors.lastname: El Atifi
authors.forename: Frédéric
authors.initials: F
authors.lastname: Mantel
authors.forename: Béatrice
authors.initials: B
authors.lastname: Rostaing
authors.forename: Annick
authors.initials: A
authors.lastname: Simon
authors.forename: François
authors.initials: F
authors.lastname: Berger
authors.forename: Daniel
authors.initials: D
authors.lastname: Seigneurin
mesh_terms: D017209:Apoptosis / Q000502:physiology; D015820:Cadherins / Q000235:genetics / Q000378:metabolism; D053181:Caspase 8; D053453:Caspase 9; D020169:Caspases / Q000378:metabolism; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D008969:Molecular Sequence Data; D020411:Oligonucleotide Array Sequence Analysis; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism; D000077294:Receptor, Transforming Growth Factor-beta Type II; D017471:Receptors, Interferon / Q000235:genetics / Q000378:metabolism; D018125:Receptors, Transforming Growth Factor beta / Q000235:genetics / Q000378:metabolism; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D016212:Transforming Growth Factor beta / Q000235:genetics / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D000096743:Interferon gamma Receptor
chemical_list: D015820:Cadherins; D053181:Caspase 8; D053453:Caspase 9; D020169:Caspases; D007371:Interferon-gamma; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D000077294:Receptor, Transforming Growth Factor-beta Type II; D017471:Receptors, Interferon; D018125:Receptors, Transforming Growth Factor beta; D047888:Receptors, Tumor Necrosis Factor, Type I; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D000096743:Interferon gamma Receptor; C505530:CASP8 protein, human; C506433:CASP9 protein, human